Market Overview

UPDATE: Citi Raises BioMarin Pharmaceuticals' PT

Related BMRN
UPDATE: UBS Securities Reiterates On BioMarin Pharmaceutical On Path To Long-Term Upside
FDA Grants BioMarin Orphan Drug Designation for NAGLU Fusion Protein, BMN 250, for the Treatment of MPS IIIB

According to a research report published this morning, Citi has increased BioMarin Pharmaceuticals' (NASDAQ: BMRN) PT from $45 to $49.

In the report, Citi said, "We hosted a lunch meeting with mgt that addresses several bear arguments. Overall, the key takeaways are: (1) the long-term tax rate will be lower than expected, (2) GALNS ph 3 should be successful, (3) mgt is talking up BMN-701 and PEG-PAL (both are upside to our TP), and (4) there will be more visibility on BMN-673 (PARP inh for ovarian cancer) in Q4:12. While many investors have been worried about mgt's body language re: GALNS and BMN-701, they seem very upbeat to us. We are raising our TP to $49 (+$4) due to a lower tax rate as their IP is domiciled abroad."

Citi maintains its Buy rating on BioMarin Pharmaceuticals, which closed Friday at $38.

Latest Ratings for BMRN

DateFirmActionFromTo
Dec 2014JP MorganMaintainsOverweight
Dec 2014UBSMaintainsBuy
Nov 2014JefferiesMaintainsBuy

View More Analyst Ratings for BMRN
View the Latest Analyst Ratings

Posted-In: CitiAnalyst Color Price Target Analyst Ratings

 

Related Articles (BMRN)

Around the Web, We're Loving...

Get Benzinga's Newsletters